John Ryan Kerrigan,Noel M. Thomsen,Artiom Cernijenko,Sarah E. Kochanek,Janetta Dewhurst,Gary O’Brien,Nathaniel F. Ware,Carina C. Sanchez,James R. Manning,Xiaolei Ma,Elizabeth Ornelas,Nikolas A. Savage,James R. Partridge,Andrew W. Patterson,Philip Lam,Natalie A. Dales,Simone Bonazzi,Sneha Borikar,Amelia E. Hinman,Pamela Y. Ting

Abstract:Sickle cell disease (SCD) is a prevalent, life-threatening condition with few treatment options, attributed to a heritable mutation in β-hemoglobin. Therapeutic induction of fetal hemoglobin (HbF) with small molecules has been pursued as a treatment to ameliorate many disease complications but with limited success. Herein, we report the discovery of 10, a novel, potent, and selective molecular glue degrader of the transcription factor WIZ that robustly induces HbF expression as a potential...

Discovery and Optimization of First-in-Class Molecular Glue Degraders of the WIZ Transcription Factor for Fetal Hemoglobin Induction to Treat Sickle Cell Disease